2026 Q3 - tulosraportti
UUTTA
Tänään
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,33%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 150 | ||
| 150 | ||
| 300 | ||
| 195 | ||
| 194 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenIs there an explanation for why it is rising more in the US than in DK?
I have at no point warned against buying the stock, but always warned against you and kim on 19, at Q2 it was supposed to go up to 400-500kr and it fell to 238kr, you lure people into buying the stock without you having any knowledge of it,
·1 t sitten · Muokattu-Mike if you are listening in. Then it is a really good time to acquire and announce that you have bought for a couple of million shares👍 yes, preferably Novo shares😊🤣🤣🤣Ali nobody from management is watching here , they don't know this forum exists , and they don't in the USA either , even though you think so 🤣🤣🤣- ·2 t sittenI am a happy little pig. Choosing red seats for my Ferrari
·2 t sitten
·2 t sitten · MuokattuI have added to my position today because: 1) Novo delivers strong cash flow (cash is king!) 2) The Wegovy pill is selling really well and is giving the Foundayo pill a well-deserved run for its money (greater weight loss, fewer side effects, less interaction risk with other medications such as birth control pills and cholesterol medication) 3) The Wegovy pill has only recently been launched in three countries outside the US, but now many new countries are being added at a rapid pace 4) Novo's large CAPEX investments are now beginning to pay off in the form of greater production capacity. And over the next 2-3 years, the need for additional CAPEX for new production capacity will decrease while production capacity continues to grow strongly 5) CagriSema is a strong product. It is completely insane that the share value in Novo has been cut by 75 % due to "CagriSema disappointments" 6) There is a soon-to-expire patent on Semaglutide, but that does not hit Novo alone. That patent expiration will put price pressure on all weight loss products, i.e., it will also hit the price of both Novo's and Lilly's still-patented products and of course also the upcoming new patented products. 7) The price pressure will also be a very major challenge for upcoming weight loss products from new companies on the market, i.e., all companies other than Novo and Lilly. In addition to development costs for new products, they must also finance new production capacity as well as marketing for these products, which will have to compete in a market with far lower prices than Novo and Lilly got when they introduced their weight loss products. 8) Novo's production capacity is surging massively now. Novo is about to be fully geared to fight on price. 9) There seem to be trends in the market indicating a sector rotation where some money is being moved away from "Tech". Currently, this sector reduction has only to a limited extent benefited Novo, whereas Lilly has done quite phenomenally. But at some point, the price difference between Lilly and Novo will become so large that I believe a minor skewed multiple price will occur between these two companies. 10) When major market corrections or crashes occur, practically all stocks fall. But Novo no longer costs > DKK 1,000 with a P/E > 40. Even if the entire stock market were to fall 50 %, I do not believe at all that this will happen to Novo with their current cash flow and their actually quite good pipeline (CagriSema is probably not a miracle cure, but it is a good product).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 50 000 | 50 000 | 0 | 50 000 |
| Danske Bank A/S | 3 000 | 3 000 | 0 | 3 000 |
| Anonyymi | 12 066 047 | 12 066 047 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 50 000 | 50 000 | 0 | 50 000 |
| Danske Bank A/S | 3 000 | 3 000 | 0 | 3 000 |
| Anonyymi | 12 066 047 | 12 066 047 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
Tänään
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,33%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIs there an explanation for why it is rising more in the US than in DK?I have at no point warned against buying the stock, but always warned against you and kim on 19, at Q2 it was supposed to go up to 400-500kr and it fell to 238kr, you lure people into buying the stock without you having any knowledge of it,
- ·1 t sitten · Muokattu-Mike if you are listening in. Then it is a really good time to acquire and announce that you have bought for a couple of million shares👍 yes, preferably Novo shares😊🤣🤣🤣Ali nobody from management is watching here , they don't know this forum exists , and they don't in the USA either , even though you think so 🤣🤣🤣
- ·2 t sittenI am a happy little pig. Choosing red seats for my Ferrari
- ·2 t sitten
- ·2 t sitten · MuokattuI have added to my position today because: 1) Novo delivers strong cash flow (cash is king!) 2) The Wegovy pill is selling really well and is giving the Foundayo pill a well-deserved run for its money (greater weight loss, fewer side effects, less interaction risk with other medications such as birth control pills and cholesterol medication) 3) The Wegovy pill has only recently been launched in three countries outside the US, but now many new countries are being added at a rapid pace 4) Novo's large CAPEX investments are now beginning to pay off in the form of greater production capacity. And over the next 2-3 years, the need for additional CAPEX for new production capacity will decrease while production capacity continues to grow strongly 5) CagriSema is a strong product. It is completely insane that the share value in Novo has been cut by 75 % due to "CagriSema disappointments" 6) There is a soon-to-expire patent on Semaglutide, but that does not hit Novo alone. That patent expiration will put price pressure on all weight loss products, i.e., it will also hit the price of both Novo's and Lilly's still-patented products and of course also the upcoming new patented products. 7) The price pressure will also be a very major challenge for upcoming weight loss products from new companies on the market, i.e., all companies other than Novo and Lilly. In addition to development costs for new products, they must also finance new production capacity as well as marketing for these products, which will have to compete in a market with far lower prices than Novo and Lilly got when they introduced their weight loss products. 8) Novo's production capacity is surging massively now. Novo is about to be fully geared to fight on price. 9) There seem to be trends in the market indicating a sector rotation where some money is being moved away from "Tech". Currently, this sector reduction has only to a limited extent benefited Novo, whereas Lilly has done quite phenomenally. But at some point, the price difference between Lilly and Novo will become so large that I believe a minor skewed multiple price will occur between these two companies. 10) When major market corrections or crashes occur, practically all stocks fall. But Novo no longer costs > DKK 1,000 with a P/E > 40. Even if the entire stock market were to fall 50 %, I do not believe at all that this will happen to Novo with their current cash flow and their actually quite good pipeline (CagriSema is probably not a miracle cure, but it is a good product).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 150 | ||
| 150 | ||
| 300 | ||
| 195 | ||
| 194 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 50 000 | 50 000 | 0 | 50 000 |
| Danske Bank A/S | 3 000 | 3 000 | 0 | 3 000 |
| Anonyymi | 12 066 047 | 12 066 047 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 50 000 | 50 000 | 0 | 50 000 |
| Danske Bank A/S | 3 000 | 3 000 | 0 | 3 000 |
| Anonyymi | 12 066 047 | 12 066 047 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
Tänään
‧1 t 3 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,33%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIs there an explanation for why it is rising more in the US than in DK?I have at no point warned against buying the stock, but always warned against you and kim on 19, at Q2 it was supposed to go up to 400-500kr and it fell to 238kr, you lure people into buying the stock without you having any knowledge of it,
- ·1 t sitten · Muokattu-Mike if you are listening in. Then it is a really good time to acquire and announce that you have bought for a couple of million shares👍 yes, preferably Novo shares😊🤣🤣🤣Ali nobody from management is watching here , they don't know this forum exists , and they don't in the USA either , even though you think so 🤣🤣🤣
- ·2 t sittenI am a happy little pig. Choosing red seats for my Ferrari
- ·2 t sitten
- ·2 t sitten · MuokattuI have added to my position today because: 1) Novo delivers strong cash flow (cash is king!) 2) The Wegovy pill is selling really well and is giving the Foundayo pill a well-deserved run for its money (greater weight loss, fewer side effects, less interaction risk with other medications such as birth control pills and cholesterol medication) 3) The Wegovy pill has only recently been launched in three countries outside the US, but now many new countries are being added at a rapid pace 4) Novo's large CAPEX investments are now beginning to pay off in the form of greater production capacity. And over the next 2-3 years, the need for additional CAPEX for new production capacity will decrease while production capacity continues to grow strongly 5) CagriSema is a strong product. It is completely insane that the share value in Novo has been cut by 75 % due to "CagriSema disappointments" 6) There is a soon-to-expire patent on Semaglutide, but that does not hit Novo alone. That patent expiration will put price pressure on all weight loss products, i.e., it will also hit the price of both Novo's and Lilly's still-patented products and of course also the upcoming new patented products. 7) The price pressure will also be a very major challenge for upcoming weight loss products from new companies on the market, i.e., all companies other than Novo and Lilly. In addition to development costs for new products, they must also finance new production capacity as well as marketing for these products, which will have to compete in a market with far lower prices than Novo and Lilly got when they introduced their weight loss products. 8) Novo's production capacity is surging massively now. Novo is about to be fully geared to fight on price. 9) There seem to be trends in the market indicating a sector rotation where some money is being moved away from "Tech". Currently, this sector reduction has only to a limited extent benefited Novo, whereas Lilly has done quite phenomenally. But at some point, the price difference between Lilly and Novo will become so large that I believe a minor skewed multiple price will occur between these two companies. 10) When major market corrections or crashes occur, practically all stocks fall. But Novo no longer costs > DKK 1,000 with a P/E > 40. Even if the entire stock market were to fall 50 %, I do not believe at all that this will happen to Novo with their current cash flow and their actually quite good pipeline (CagriSema is probably not a miracle cure, but it is a good product).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 150 | ||
| 150 | ||
| 300 | ||
| 195 | ||
| 194 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 50 000 | 50 000 | 0 | 50 000 |
| Danske Bank A/S | 3 000 | 3 000 | 0 | 3 000 |
| Anonyymi | 12 066 047 | 12 066 047 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 50 000 | 50 000 | 0 | 50 000 |
| Danske Bank A/S | 3 000 | 3 000 | 0 | 3 000 |
| Anonyymi | 12 066 047 | 12 066 047 | 0 | 0 |